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Abstract
AIM: To test whether oral L-81 treatment could im-
prove the condition of mice with diabetes and to in-
vestigate how L-81 regulates microsomal triglyceride 
transfer protein (MTP) activity in the liver.
METHODS: Genetically diabetic (db /db ) mice were 
fed on chow supplemented with or without L-81 for 
4 wk. The body weight, plasma glucose level, plasma 
lipid profile, and adipocyte volume of the db/db  mice 
were assessed after treatment. Toxicity of L-81 was 
also evaluated. To understand the molecular mecha-
nism, HepG2 cells were treated with L-81 and the ef-
fects on apolipoprotein B (apoB) secretion and mRNA 
level of the MTP gene were assessed.
RESULTS: Treatment of db /db  mice with L-81 sig-
nificantly reduced and nearly normalized their body 
weight, hyperphagia and polydipsia. L-81 also markedly 
decreased the fasting plasma glucose level, improved 
glucose tolerance, and attenuated the elevated levels 
of plasma cholesterol and triglyceride. At the effec-
tive dosage, little toxicity was observed. Treatment of 
HepG2 cells with L-81 not only inhibited apoB secretion, 
but also significantly decreased the mRNA level of the 
MTP gene. Similar to the action of insulin, L-81 exerted 
its effect on the MTP promoter.
CONCLUSION: L-81 represents a promising candidate 
in the development of a selective insulin-mimetic mol-
ecule and an anti-diabetic agent.
© 2009 The WJG Press and Baishideng. All rights reserved.
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INTRODUCTION
Pluronic® surfactants or poloxamers are synthetic 
copolymers based on ethylene oxide and propylene 
oxide. They are synthesized by controlled addition 
of  propylene oxide to the two hydroxyl groups of  
propylene glycol[1]. Pluronic surfactants are widely used 
in industries as defoaming and antifoaming agents in 
dishwashing, antifreeze, cutting and grinding fluids, water 
treatment, etc. They are also being investigated as drug 
delivery vectors[2] and cancer therapies[3]. Pluronic L-81 
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(L-81) contains 10% hydrophilic and 90% hydrophobic 
polyoxyethylene residues with a molecular weight of  
2750.
L-81 has profound effects on the lipid metabolism 
of  the intestine and the liver. Chronic feeding of  rats 
with L-81 greatly reduced the lymphatic lipid transport 
from their intestine, without affecting the digestion and 
absorption of  lipid into enterocytes. The absorbed lipid 
was however accumulated in the enterocytes, suggesting 
that L-81 interferes with lipoprotein assembly and/or 
exit of  lipoproteins from the mucosal cells[4]. L-81 
inhibits chylomicron formation but not very low density 
lipoprotein (VLDL) assembly in the intestine[5]. On the 
other hand, L-81 effectively inhibits VLDL and low-
density lipoprotein (LDL) secretion in hepatocytes[6]. 
Assembly of  VLDL in hepatocytes depends very much 
on the endoplasmic reticulum-residing protein microsomal 
triglyceride transfer protein (MTP). There is evidence that 
L-81 inhibits MTP activity in hepatocytes[7]. Consistent 
with these molecular effects, rodents fed with L-81 
exhibited obvious weight loss, which is reversible upon 
withdrawal of  the compound in the diet[4,8]. Because the 
inhibitory effect of  L-81 on lipid transport is rapid and 
readily reversible, it is an attractive drug for controlling 
obesity.
Obesity, defined as a body mass index exceeding 
30 kg/m2, is epidemic in many developed countries. 
For instance, more than 50% of  the adults in the USA 
are either overweight or obese[9]. Obesity is a strong 
risk factor for the development of  insulin resistance 
and type 2 diabetes[10]. The risk of  developing type 2 
diabetes increases in parallel with increasing severity of  
overweight and obesity[11]. On the other hand, weight 
reduction is associated with a decreased incidence of  
type 2 diabetes[12]. Obesity is also strongly associated 
with cardiovascular diseases and cancers[13]. Clearly, it 
would be of  great clinical benefit if  effective prevention 
and treatments for obesity and associated type 2 diabetes 
were established. 
Although L-81 is a potent anti-obesity drug, its 
potential in alleviating obesity-induced insulin resistance 
and type 2 diabetes has not been fully explored. Here 
we aimed to test whether L-81 could ameliorate diabetic 
symptoms using a mouse model of  type 2 diabetes, 
db/db mice. db/db mice have a mutant leptin receptor 
which results in high plasma triglyceride and cholesterol 
levels. db/db mice develop significant obesity, fasting 
hyperglycemia and hyperinsulinemia within 6 wk of  
age[14]. We also investigated the possibility that L-81 
affects MTP activity through transcription regulation.
MATERIALS AND METHODS
Cell culture and measurement of apoB secretion rates in 
HepG2 cells 
HepG2 cells were obtained from the American Type 
Culture Collection (ATCC) and maintained in basal 
medium (MEM supplemented with 1.5 g/L sodium 
bicarbonate, 2 mmol/L glutamate, 2 mmol/L sodium 
pyruvate) with 10% FBS. In a typical experiment, cells 
were seeded into 6-well (35 mm) culture plates, allowed 
to grow to 70% confluence, and then incubated with 
3 mL of  either the control medium (basal medium sup-
plemented with 3% BSA) or experimental media (control 
medium plus test substances) at 37? for the indicated 
time. At the end of  the experiments, media were collect-
ed and analyzed for apolipoprotein B (apoB) and apoA-I 
by ELISA as described previously[15]. 
Measurement of human MTP and actin mRNA levels 
Total RNA was isolated from HepG2 cells by the 
guanidinium thiocyanate method and the relative levels 
of  the MTP large subunit and β-actin mRNA were 
determined by the DNA excess solution hybridization 
assays as described previously[15]. 
MTP promoter construct, transfection and reporter assay 
The promoter-luciferase construct (MTP-250) which 
contains a 336-bp fragment encompassing position -250 
to +86 of  the human MTP promoter was generated by 
PCR as described in our earlier study[16] and cloned into 
promoterless pGL3-Basic vector (Promega, Madison, 
WI). For transfection, HepG2 cells were grown overnight 
(70% confluent) in 6-well plates and washed twice with 
serum-free medium. DNA-lipofectAMINE 2000 com-
plexes, containing 1 μg MTP promoter-firefly luciferase 
construct, 0.1 μg pRL-SV40 renilla luciferase control vec-
tor, and 2 μg lipofectAMINE 2000 (Invitrogen) in 200 μL 
serum-free medium in each well, were allowed to form at 
room temperature for 30 min. The cells were then overlaid 
with the complex for 6 h at 37?. After 16 h of  recovery 
in complete culture medium, the cells were washed twice 
with serum-free medium, and experimental media with or 
without the indicated concentration of  Pluronic L-81 were 
subsequently added. After 24 h, the cells were washed 
twice with ice-cool PBS and treated with passive lysis buf-
fer (Pormega, Madison, WI). The lysates were assayed for 
both luciferase activities using the Dual-luciferase assay kit 
(Pormega, Madison, WI) according to the manufacturer’s 
instructions. Luciferase activities were determined by Lu-
mat LB 9507 luminometer (Berthold).
Animals and L-81 treatment 
Male and genetically diabetic BKS· Cg-m +/+ Leprdb (db/
db) mice and their non-diabetic littermates C57BLKS/
J (BKS) (5-6 wk of  age; n = 3 mice per group) were 
obtained from Jackson Laboratories (Bar Harbor, 
ME). They were housed in environmentally controlled 
conditions with a 12-h light/dark cycle. Mice were fed 
a standard rodent chow diet (powdered) and water ad 
libitum in sterile cages. Animals were gathered together 
for 2 wk before the commencement of  the experiment. 
Pluronic L-81 was kindly provided by BASF Corporation 
(Parsippany, NJ). To prepare food with the indicated 
amount of  L-81 for treatment, L-81 was first dissolved 
in ethanol and sprayed on the powdered chow. The food 
was then air-dried to remove the carrier ethanol before 
it was used to feed the mice. Various parameters of  the 
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mice including body weight, food and water intake were 
monitored on a regular basis as indicated.
Animal blood sampling, metabolic measurements, 
intraperitoneal glucose tolerance test (IPGTT), and 
histological analysis 
Animals (n = 3 mice per group) were fasted for 5 h 
before blood was sampled from the retro-orbital sinus. 
Plasma glucose, insulin, adiponectin, triglycerides, 
cholesterol, alkaline phosphatase (ALP), alanine 
aminotransferase (ALT) levels were measured using 
standard enzyme assay kits. For IPGTT, mice were 
first fasted for 5 h and then received an intraperitoneal 
administration of  glucose (2 g/kg). Blood glucose levels 
were determined using the One-touch Ultra Blood 
Glucose Monitoring System (LifeScan Inc) from the tail 
blood samples at 0 (before glucose administration), 30, 
60, 90, and 120 min after glucose administration. Tissues 
were collected and fixed in 10% phosphate-buffered 
formalin for histological analysis. Paraffin-embedded 
tissues were sectioned (5 μm thick) and stained with 
hematoxylin and eosin (HE) using standard procedures.
Statistical analysis 
For each animal experiment, C57 lean mice and db/db 
mice (n = 3 mice per group) were either untreated (con-
trol) or treated with different concentrations of  L-81 
or 0.005% rosiglitazone (rosig). The experiment was 
performed 3 times to obtain data with statistical signifi-
cance. Data shown were obtained from at least 3 inde-
pendent experiments and presented as mean ± SD. One-
way analysis of  variance (ANOVA) was used to compare 
multiple experimental groups. Differences were consid-
ered to be statistically significant when P < 0.05.
RESULTS
L-81 treatment induced weight loss and ameliorated 
diabetes
The nonionic surfactant L-81 has been shown to be an 
effective weight-reducing drug in rats[4,8]. We observed 
a similar effect in db/db mice. Thus, while db/db mice 
weighed 40 g on average at 5-6 wk of  age, and their 
weight continued to increase during observation, mice 
treated with 1% or 1.5% L-81 for 30 d lost weight to a 
small extent (n = 3 mice per group) (Figure 1A and B). 
Their plasma total cholesterol and plasma triglycerol (TG) 
were also reduced by L-81 treatment (Figure 1C and 
D). Examination of  their epididymal fat pads revealed 
that adipocytes in mice treated with L-81 were smaller 
than in the db/db controls, although they were still larger 
than those in C57 lean control mice (Figure 1E). These 
data showed that L-81 is, as already found in rats, a 
hypolipidemic agent in db/db mice.
While the weight control effect of  L-81 is well 
documented, its implication in diabetes control is less 
well understood. So we asked, given the fact that L-81 
is effective in control of  obesity, is it able to ameliorate 
diabetes? To answer this we measured some diabetic 
parameters in L-81 treated db/db mice. In this study, we 
compared L-81 with rosig, a peroxisome proliferator-
activated receptor gamma (PPAR-γ) agonist and an anti-
diabetes drug[17]. 
Hyperphagia and polydipsia are two common symp-
toms of  diabetes. We first observed whether a 4-wk 
L-81 treatment could affect the feeding and drinking 
behaviors of  the mice. Compared with lean controls, 
db/db mice ingested about 2 g more food and 4 g more 
water per day. Inclusion of  1% or 1.5% L-81, or 0.005% 
of  rosig in their diet could reduce their food and water 
intake to the lean control level (Figure 2A and B).
Fasting plasma glucose levels of  the mice were mea-
sured at the beginning and the end of  a 21 d treatment 
period. As shown in Figure 2C, db/db mice exhibited el-
evated fasting blood glucose levels of  about 25 mmol/L, 
as compared with 10 mmol/L in lean controls. Twenty 
one days of  rosig or L-81 treatment reduced this pa-
rameter to near the lean control level (Figure 2C). db/db 
mice have a typical diabetic blood glucose profile after 
glucose injection (Figure 2D). Rosig or L-81-treated mice 
showed improved glucose tolerance, thus their blood 
glucose level started to drop slightly or stopped increas-
ing at 30 min after injection (Figure 2D). However, the 
levels were never as low as in lean control mice.
db/db mice are insulin-resistant and therefore have 
an elevated plasma insulin level[14]. We found that db/db 
mice treated for 21 d with rosig or L-81 exhibited a 
lowered plasma insulin concentration (Figure 2E). The 
effects of  rosig and L-81 were comparable. Rosig effec-
tively increased the plasma level of  adiponectin, an adi-
pocytokine responsible for increasing tissue sensitivity to 
insulin. This, however, was not observed in L-81 treated 
mice (Figure 2F). Taken together, oral L-81 treatment 
can effectively improve diabetic symptoms in the db/db 
mouse model.
L-81 inhibited MTP transcription
L-81 treated cells show decreased activity of  MTP. 
However MTP purified from those cells exhibited 
normal TG transfer activity[7], suggesting that L-81 does 
not affect MTP activity post-translationally. We have 
shown previously that MTP activity is largely controlled 
at the transcription level[15]. We therefore wished to 
address the possibility that L-81 controls MTP activity 
by modulating the transcription of  the MTP gene. To 
do this we transiently transfected a MTP promoter-
luciferase reporter construct as previously described[16] 
into HepG2 and treated the cells with L-81.
As shown in Figure 3A, the expression of  luciferase 
driven by the full-length MTP promoter (-612 to +86) 
was reduced by about 25% in the presence of  1% L-81. 
This figure agrees with that observed previously[7]. Given 
that MTP plays an essential role in the assembly and 
secretion of  apoB-containing lipoproteins, we tested the 
effect of  L-81 on apoB secretion in HepG2 cells. As 
shown in Figure 3B, L-81 dose-dependently inhibited 
the apoB secretion in HepG2 cells, while no significant 
changes were obser ved in apoA-I secret ion. By 
examining the cell morphology, lactate dehydrogenase 
activity (a marker of  necrosis), and total cellular proteins 
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in HepG2 cells, we also determined that in vitro L-81 
treatment (0-3 μmol/L) had little or no cytotoxic effect 
on the cells (data not shown). Taken together, these 
results demonstrated that L-81 causes a reduction of  
apoB secretion in HepG2 cells at least partly via the 
inhibition of  MTP expression. 
To locate the sequence element responsible for 
mediating the inhibitory effect of  L-81 on MTP 
promoter, we transfected HepG2 cells with various MTP 
promoter/luciferase reporter deletion constructs (see 
Figure 3A), and their relative promoter activities were 
determined from the cells treated with 1% L-81. It was 
found that the inhibitory effect of  L-81 (and insulin) 
persists up to the deletion construct MTP-115 (Figure 
3A), suggesting that L-81 (and insulin) responsive 
sequence resides between -102 and -115. A mutation of  
promoter sequence -102 to -108 [where a hepatocyte 
nuclear factor (HNF)-1 site is located] abolished 
the inhibitory effect, suggesting that this region is 
responsible for mediating the inhibition. Either deletion 
or mutation of  the HNF-1 site caused an almost 
complete shutdown of  the MTP promoter activity 
(Figure 3A), indicating that this site is involved not only 
in the regulation but also in the basal expression of  the 
MTP gene.
L-81 caused no detectable toxicity to the liver
Pharmacological inhibition of  MTP transcription has been 
explored as a means of  treating dyslipidemia. It is believed 
that by interfering with hepatic and intestinal VLDL 
packaging, MTP transcription inhibitors would reduce 
the plasma level of  VLDL. Many MTP transcription 
www.wjgnet.com
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Figure 1  L-81 reduced obesity. A: Body appearances of lean control (left), untreated db/db (middle), and db/db mice fed with chow sprayed with 1% L-81 (right); B: 
Weight of db/db mice or lean control mice receiving different drug treatments over an observation period of 30 d (n = 3 in each group); C: Plasma total cholesterol and (D) 
plasma triglyceride level of mice treated with the indicated drugs; E: The size of adipocytes in epididymal fat pads of mice treated with the indicated drugs as observed 
under 100 × magnification.
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inhibitors have been developed and put into clinical 
trials. However, from the clinical trial data, it is obvious 
that MTP transcription inhibitors very often cause 
hepatosteatosis (fatty liver)[18]. We were hence concerned 
whether L-81’s MTP transcription inhibitory effect would 
lead to hepatosteatosis and a decline of  liver function. 
To check whether L-81 treatment caused any gross 
hepatic injury, we measured the plasma ALT level of  
www.wjgnet.com
Figure 2  L-81 ameliorated diabetes. A: Food intake and (B) water intake of mice fed on a chow diet, with or without the indicated drugs (n = 3 in each group); C: Fasting 
plasma glucose levels of lean control mice or db/db mice treated with L-81 or rosig before and after a 21 d treatment of the indicated drugs; D: Glucose tolerance of mice 
treated with the indicated drugs. Mice injected with glucose had their blood glucose level monitored by Onetouch Ultra Blood Glucose Monitoring system; E: Plasma insulin 
level of db/db mice treated with the indicated drugs for 4 wk; F: Plasma adiponectin level of db/db mice treated with the indicated drugs for 4 wk. aP < 0.05 compared with 
untreated control.
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db/db C57L mice after 21 d of  L-81 treatment. In lean 
control mice, the presence of  L-81 in the diet did not 
cause any significant difference in the plasma ALT 
level, indicating that L-81 did not induce liver injury 
(Figure 4A). Interestingly, we found that while db/db 
mice generally have a higher level of  plasma ALT than 
C57L lean control mice, L-81 treatment did not result 
in any significant difference (Figure 4A). Histological 
examination of  the livers of  the mice revealed that L-81 
treatment caused neither an enlargement of  the liver nor 
any microscopic damage to the liver (Figure 4C).
Conditioned taste aversion (CTA) is a commonly 
used test to assess whether a particular substance or 
treatment would render animals ill. L-81 treated mice 
consumed 72% of  their total fluid intake as saccharin 
in the 2-bottle test, a ratio comparable to that of  the 
untreated db/db mice (Figure 4B). Treatment with 
rosig gave a similar response (Figure 4B). In contrast, 
administration with lithium chloride produced a robust 
CTA (Figure 4B). Taken together, we have not observed 
any toxicity associated with L-81 treatment.
DISCUSSION
The prevalence of  obesity is now escalating globally 
and insulin resistance resulting from the increased fat 
mass has been identified as a key factor that could drive 
parallel increases in T2DM[19]. The prevalence of  T2DM 
has reached a pandemic situation in which it is estimated 
to affect > 6% of  the world population. Clinically, 
patients with T2DM display not only an elevated level 
of  blood glucose, but also an elevated level of  plasma 
lipids. These abnormal levels of  circulating lipids are 
the primary cause of  severe macrovascular diseases 
with poor prognosis, which is responsible for 80% of  
diabetic mortality and 75% of  all hospitalizations for 
diabetic complications[20]. Indeed, diabetes is recognized 
as a coronary heart disease “risk equivalent”, and the 
risk of  myocardial infarction in diabetic patients is 
equal to those of  non-diabetic patients with known 
cardiac diseases[21]. Thus, new therapeutic strategies 
for the treatment of  diabetes should not aim only to 
lower blood glucose level, but also to address diabetes-
associated lipid disorders.
Our present study provides evidence for the first 
time that L-81 is not only a potent lipid-lowering 
compound but also an anti-diabetic agent in db/db 
mice. L-81 normalizes the levels of  plasma lipids and 
reduces fat mass, and thereby attenuates obesity which is 
essentially linked to insulin resistance and a number of  
serious diabetes-associated macrovascular disorders such 
as coronary, cerebral and peripheral artery diseases[20]. 
The ability of  L-81 to attenuate obesity may play an 
important role in mediating its antidiabetic effects in 
db/db mice. In fact, the relationship between obesity 
and insulin resistance/T2DM has been linked in a cause 
and effect association, as weight loss or gain correlates 
closely with increasing or decreasing insulin sensitivity, 
respectively[22-24].
Moreover, L-81 significantly improved fasting 
glycemic control and glucose tolerance in db/db mice. 
It also reduced hyperphagia and polydipsia, which are 
symptoms of  diabetes mellitus. Remarkably, L-81 caused 
neither hepatotoxicity nor apparent sickness during the 
course of  treatment. The fact that treatment with L-81 
decreased food intake in the db/db mice is likely to be 
an element of  the therapeutic action of  L-81. Earlier 
studies showed that L-81 treatment did not affect food 
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Figure 4  L-81 was not toxic to the liver. A: Plasma ALT level of mice treated with the indicated drugs; B: CTA test of mice treated with the indicated drugs; C: 
Histological examinations of db/db mice treated with indicated drugs. aP < 0.05 compared with untreated db/db.
Untreated db/db                     1% L-81 treated db/db             Rosig treated db/db   1.5% L-81 treated db/dbC
Untreated db/db
1% L-81, db/db
1.5% L-81, db/db
0.005% rosig, db/db
Untreated lean control
1% L-81, lean control
120
100
80
60
40
20
0
Al
an
in
e 
tr
an
sa
m
in
as
e 
(I
U
)
  0            21
  Days after treatment
A
a
100
75
50
25
0
Ra
tio
 o
f 
su
ga
r 
so
lu
tio
n 
to
 
to
ta
l fl
ui
d 
in
ta
ke
 (
%
)
Unt
rea
ted
, db
/db
B
1%
 L-8
1, d
b/d
b
Ros
ig, 
db/
db
Unt
rea
ted
, C5
7
LiC
i, db
/db
2992     ISSN 1007-9327      CN 14-1219/R     World J Gastroenterol      June 28, 2009     Volume 15     Number 24
consumption in lean mice[8,25]. Our data on the lean mice 
are consistent with this previous observation. Compared 
with rosig, a PPAR-γ agonist[17] and a well marketed anti-
diabetic drug, L-81 exhibited comparable potency in 
lipid and glycemic control without eliciting overt weight 
gain which is the side effect of  the former[26,27]. 
Consistent with previous studies, we observed that 
treatment with L-81 led to an accumulation of  lipid 
stored in intestinal villi. Since the turnover rate of  the 
intestinal epithelial lining is rapid, the excess lipids may 
be excreted together with obsolete cells. It is believed 
that the intestine is the principal site of  action of  L-81 
when the drug is included in the diet[8,25]. Functionally, 
L-81 impairs the transepithelial lipid flux during fat 
absorption and arrests the trafficking of  apoB-containing 
lipoproteins within the enterocytes, which leads to a 
cytosolic and endoplasmic reticulum lipid accumulation 
and thereby prevents the absorption of  lipids[4,28,29]. This 
action appears to be selective and does not affect other 
lipid metabolism such as fatty acid synthesis, cholesterol 
re-esterification, and more importantly the absorption 
of  other nutrients[4,5,29,30]. Taken together, our present 
results indicate that L-81 exhibits prominent antidiabetic 
activities in the diabetic db/db mice and suggest that 
L-81 may represent a new class of  anti-diabetic agent 
conferring both efficacy and safety.
MTP exists in the lumen of  the endoplasmic reticulum 
as a heterodimer with protein-disulfide isomerase and 
plays a pivotal role in the assembly and secretion of  
the apoB-containing lipoproteins[31]. Our in vitro studies 
showed that L-81 treatment induced a significant 
reduction in apoB secretion of  HepG2 cells, at least 
partly via the inhibition of  MTP gene expression. We 
also found that the expression of  MTP transcripts in the 
liver of  L-81-treated mice was significantly decreased, 
supporting our in vitro data which demonstrated that 
L-81 could reduce MTP expression. These results 
indicated that attenuation of  the MTP gene expression 
by L-81 may partially contribute to the improvement of  
the lipid profiles in diabetic db/db mice. Moreover, we 
showed that L-81 inhibited MTP promoter activity, in 
a similar fashion as insulin, in L6 cells with an enforced 
expression of  HNF-1α, suggesting that L-81 mimics 
insulin action and exerts an inhibitory effect on the MTP 
gene via the same HNF-1 element. 
We have previously shown that the consensus 
HNF-1 element is functionally equivalent to the slightly 
modified HNF-1 element found on the MTP promoter 
in mediating the negative insulin response[32]. This 
finding implies that the HNF-1-mediated negative 
insulin response is not only limited to the MTP gene 
but also to other genes containing the HNF-1 binding 
motif. In addition to the MTP gene, the transcription of  
other HNF-1-containing genes may be elevated under 
diabetic conditions, which could potentially result in 
abnormal lipid and glucose metabolism and elevated 
plasma triglyceride, cholesterol and glucose levels. 
Thus, compounds like L-81 that can mimic the insulin 
effect and suppress the transcription of  MTP and 
other HNF-1-containing genes should provide relief  
to these syndromes. Since HNF-1α contributes to the 
transcriptional regulation of  many rate-limiting steps in 
gluconeogenesis and also binds to genes whose products 
are central to normal hepatic functions, including 
carbohydrate synthesis and storage, lipid metabolism, 
detoxification, and synthesis of  serum proteins[33], the 
potential regulation of  these genes by L-81 warrants 
further investigation in order to gain more insight into 
the mechanisms of  L-81 action.
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